Gamida Cell Ltd.
Gamida Cell Ltd. (GMDA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gmda · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Gamida Cell Ltd.You GMDA | $4M | N/A | — | — |
 Aptose Biosciences Inc. APTO | $4M | N/A | — | $0.00 |
 Atreca, Inc. BCEL | $4M | N/A | — | -$2.52 |
 Altamira Therapeutics Ltd. CYTO | $1M | N/A | — | $0.00 |
 Gritstone bio, Inc. GRTS | $4M | N/A | — | -$1.20 |
 Hillstream BioPharma, Inc. HILS | $4M | N/A | — | -$1.12 |
 Idera Pharmaceuticals, Inc. IDRA | $0M | N/A | — | -$7.17 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Gamida Cell Ltd. (GMDA) measures how much investors pay for each dollar of the company's trailing earnings. GMDA's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of —.
Frequently asked questions
GMDA pe ratio · 6 questionsGMDA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.03 and TTM EPS of —. Data sourced from Financial Modeling Prep via GMDA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Gamida Cell Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09